Bionano Genomics Stock Probability of Future Stock Price Finishing Over 0.24

BNGO Stock  USD 0.24  0.01  4.00%   
Bionano Genomics' future price is the expected price of Bionano Genomics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Bionano Genomics performance during a given time horizon utilizing its historical volatility. Check out Bionano Genomics Backtesting, Bionano Genomics Valuation, Bionano Genomics Correlation, Bionano Genomics Hype Analysis, Bionano Genomics Volatility, Bionano Genomics History as well as Bionano Genomics Performance.
To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.
  
As of the 26th of November 2024, Price To Sales Ratio is likely to drop to 1.70. In addition to that, Price Earnings Ratio is likely to drop to -0.29. Please specify Bionano Genomics' target price for which you would like Bionano Genomics odds to be computed.

Bionano Genomics Target Price Odds to finish over 0.24

The tendency of Bionano Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.24 90 days 0.24 
more than 93.0
Based on a normal probability distribution, the odds of Bionano Genomics to move above the current price in 90 days from now is more than 93.0 (This Bionano Genomics probability density function shows the probability of Bionano Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.78 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bionano Genomics will likely underperform. Additionally Bionano Genomics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Bionano Genomics Price Density   
       Price  

Predictive Modules for Bionano Genomics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bionano Genomics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.010.215.45
Details
Intrinsic
Valuation
LowRealHigh
0.173.498.73
Details
Naive
Forecast
LowNextHigh
00.215.44
Details
4 Analysts
Consensus
LowTargetHigh
12.0113.2014.65
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bionano Genomics. Your research has to be compared to or analyzed against Bionano Genomics' peers to derive any actionable benefits. When done correctly, Bionano Genomics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Bionano Genomics.

Bionano Genomics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Bionano Genomics is not an exception. The market had few large corrections towards the Bionano Genomics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bionano Genomics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bionano Genomics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-1.34
β
Beta against Dow Jones2.78
σ
Overall volatility
0.09
Ir
Information ratio -0.22

Bionano Genomics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bionano Genomics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bionano Genomics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Bionano Genomics generated a negative expected return over the last 90 days
Bionano Genomics has high historical volatility and very poor performance
Bionano Genomics has some characteristics of a very speculative penny stock
Bionano Genomics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 36.12 M. Net Loss for the year was (232.49 M) with profit before overhead, payroll, taxes, and interest of 5.95 M.
Bionano Genomics currently holds about 187.34 M in cash with (125.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Bionano Genomics has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Bionano Genomics stock hits 52-week low at 0.2 By Investing.com - Investing.com Australia

Bionano Genomics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bionano Stock often depends not only on the future outlook of the current and potential Bionano Genomics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bionano Genomics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding34.1 M
Cash And Short Term Investments101.9 M

Bionano Genomics Technical Analysis

Bionano Genomics' future price can be derived by breaking down and analyzing its technical indicators over time. Bionano Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Bionano Genomics. In general, you should focus on analyzing Bionano Stock price patterns and their correlations with different microeconomic environments and drivers.

Bionano Genomics Predictive Forecast Models

Bionano Genomics' time-series forecasting models is one of many Bionano Genomics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Bionano Genomics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Bionano Genomics

Checking the ongoing alerts about Bionano Genomics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Bionano Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Bionano Genomics generated a negative expected return over the last 90 days
Bionano Genomics has high historical volatility and very poor performance
Bionano Genomics has some characteristics of a very speculative penny stock
Bionano Genomics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 36.12 M. Net Loss for the year was (232.49 M) with profit before overhead, payroll, taxes, and interest of 5.95 M.
Bionano Genomics currently holds about 187.34 M in cash with (125.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Bionano Genomics has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Bionano Genomics stock hits 52-week low at 0.2 By Investing.com - Investing.com Australia
When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.30)
Revenue Per Share
0.749
Quarterly Revenue Growth
(0.10)
Return On Assets
(0.33)
Return On Equity
(1.38)
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.